Economic growth has slowed in China, volume-based pricing (VBP) is affecting overseas companies’ abilities to compete on a level playing and systemic state support at high levels is offered to the local industry. At the same time, the government has set targets for more home grown medtech players to become established among the leading global companies by revenues.
It is a potential minefield for non-Chinese multinationals wishing to expand into, or further within, the market. But global medtech...